Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
dc.contributor.author | Li, Wei | |
dc.contributor.author | Risacher, Shannon L. | |
dc.contributor.author | Gao, Sujuan | |
dc.contributor.author | Boehm, Stephen L. | |
dc.contributor.author | Elmendorf, Jeffrey S. | |
dc.contributor.author | Saykin, Andrew J. | |
dc.contributor.department | Radiology and Imaging Sciences, School of Medicine | en_US |
dc.date.accessioned | 2018-06-08T20:38:12Z | |
dc.date.available | 2018-06-08T20:38:12Z | |
dc.date.issued | 2017-11-23 | |
dc.description.abstract | Introduction Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease. Cerebrospinal fluid (CSF) amyloid β (Aβ) 1-42 is an important Alzheimer's disease biomarker. However, it is inconclusive on how T2DM is related to CSF Aβ1-42. Methods Participants with T2DM were selected from the Alzheimer's Disease Neuroimaging Initiative by searching keywords from the medical history database. A two-way analysis of covariance model was used to analyze how T2DM associates with CSF Aβ1-42 or cerebral cortical Aβ. Results CSF Aβ1-42 was higher in the T2DM group than the nondiabetic group. The inverse relation between CSF Aβ1-42 and cerebral cortical Aβ was independent of T2DM status. Participants with T2DM had a lower cerebral cortical Aβ in anterior cingulate, precuneus, and temporal lobe than controls. Discussion T2DM is positively associated with CSF Aβ1-42 but negatively with cerebral cortical Aβ. The decreased cerebral cortical Aβ associated with T2DM is preferentially located in certain brain regions. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Li, W., Risacher, S. L., Gao, S., Boehm, S. L., Elmendorf, J. S., & Saykin, A. J. (2017). Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer’s disease biomarker amyloid β1-42 in Alzheimer’s Disease Neuroimaging Initiative participants. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring, 10, 94–98. https://doi.org/10.1016/j.dadm.2017.11.002 | en_US |
dc.identifier.issn | 2352-8729 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/16456 | |
dc.language.iso | en_US | en_US |
dc.relation.isversionof | 10.1016/j.dadm.2017.11.002 | en_US |
dc.relation.journal | Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
dc.source | PMC | en_US |
dc.subject | Alzheimer's disease | en_US |
dc.subject | Amyloid β | en_US |
dc.subject | Aβ1-42 | en_US |
dc.subject | Cerebrospinal fluid (CSF) | en_US |
dc.subject | Type 2 diabetes mellitus | en_US |
dc.title | Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants | en_US |
dc.type | Article | en_US |